MGMT and glioblastoma: Finally, the DNA methylation status of O6-methylguanine-DNA methyltransferase (MGMT) is widely used as a predictive biomarker for therapeutic response to the alkylating agent, temozolomide, and as a prognostic marker in glioblastoma patients [55, 58].